Kisspeptin is the upstream switch of the reproductive hormone axis — here is the published evidence.

What is kisspeptin?

Kisspeptin is a neuropeptide family encoded by the KISS1 gene. The primary precursor protein — 145 amino acids — is cleaved to produce the 54-amino-acid isoform (KP-54) and shorter fragments including KP-14, KP-13, and KP-10. All isoforms share a conserved C-terminal RF-amide motif (Arg-Phe-NH₂) required for receptor binding.^[1]

The receptor: KISS1R, formerly designated GPR54. It is a Gq/11-coupled G-protein-coupled receptor expressed on hypothalamic GnRH neurons. When kisspeptin binds KISS1R, it activates phospholipase C, triggering IP3-mediated calcium release that depolarizes the GnRH neuron by approximately 6 mV, sustaining elevated firing for about 21 minutes.^[4]

GnRH neurons, once activated, release gonadotropin-releasing hormone into the hypothalamic-pituitary portal system. The pituitary responds with LH and FSH secretion; the gonads respond with testosterone and estradiol production. Kisspeptin initiates this entire cascade.

Kisspeptin is not FDA-approved for any clinical indication as of 2025. It is the subject of an active and growing research literature, which is what this site documents.^[22]

What is kisspeptin used for in research?

Five clinical research arms have generated published peer-reviewed data on kisspeptin:

Puberty and reproductive axis genetics. Loss-of-function KISS1R mutations cause idiopathic hypogonadotropic hypogonadism and absent puberty onset (Seminara 2003, NEJM).^[1] Gain-of-function KISS1R mutations cause central precocious puberty (Teles 2008, NEJM).^[2] Inactivating KISS1 mutations cause hypogonadotropic hypogonadism and pubertal failure (Topaloglu 2012, NEJM).^[3]

Hypothalamic amenorrhea and fertility restoration. Kisspeptin-54 infusion restored pulsatile LH secretion in women with hypothalamic amenorrhea — mean LH pulse frequency rose approximately 3-fold, pulse secretory mass approximately 6-fold versus vehicle (Jayasena 2014, JCEM).^[7] See kisspeptin and fertility research.

IVF oocyte maturation triggering. Kisspeptin-54 at 9.6 nmol/kg SC triggered oocyte maturation in 95% of high-OHSS-risk IVF patients with zero OHSS cases at any tested dose and a live birth rate of 62% at the optimal dose (Abbara 2015, JCEM).^[9]

Hypogonadism and testosterone. IV kisspeptin-10 (1.5 µg/kg/h infusion) raised mean LH from 5.2 to 14.1 IU/L and elevated serum testosterone in healthy men (George 2011, JCEM).^[5] In men with type 2 diabetes and biochemical hypogonadism, 0.3 µg/kg IV bolus normalized LH and testosterone over an 11-hour study period (George 2013, Clinical Endocrinology).^[6]

Psychosexual disorders. fMRI showed kisspeptin-54 modulated brain activity across the sexual-response network (Cohen d = 0.81) and increased penile tumescence by 56% above placebo in men with hypoactive sexual desire disorder (Mills 2023, JAMA Network Open).^[13] A parallel trial in women with HSDD found hippocampal and posterior cingulate modulation correlating with reduced sexual dysfunction distress and aversion (Thurston 2022, JAMA Network Open).^[14]

Kisspeptin Benefits Reported in Research

The term "benefits" maps to specific measured outcomes in the published literature. What follows are trial-documented effects, not claims of therapeutic efficacy.

LH and testosterone elevation. In healthy men, IV kisspeptin-10 produced dose-dependent LH rises within minutes of bolus administration; continuous infusion raised LH pulse frequency from 0.7 to 1.0 pulses/hour and elevated testosterone.^[5] The mechanism is upstream: kisspeptin stimulates GnRH, which stimulates LH; kisspeptin does not supply hormones directly.

Fertility-axis restoration. In women with hypothalamic amenorrhea, kisspeptin-54 infusion temporarily restored LH pulsatility — the precondition for ovulation.^[7] Pulsatile SC protocols were subsequently explored to address tachyphylaxis.

IVF safety profile. In high-OHSS-risk IVF patients, kisspeptin-54 triggered oocyte maturation without the receptor-direct ovarian stimulation that makes hCG-triggered OHSS a concern. No moderate, severe, or critical OHSS cases occurred at any tested dose across the Phase 2 RCT.^[9]

Safety record. A 2025 systematic review found no serious adverse events across more than 1,000 kisspeptin administrations across multiple centers.^[22] A 2025 crossover trial in 95 participants confirmed biologically active kisspeptin-54 did not increase state anxiety, cortisol, or blood pressure versus placebo.^[21]

For dosing protocols used in these studies, see kisspeptin dosage.

What does taking kisspeptin do?

Kisspeptin stimulates GnRH release from the hypothalamus. GnRH then stimulates pituitary secretion of LH and FSH. LH drives testosterone production in men and triggers ovulation in women; FSH supports follicular development and spermatogenesis.

In published human studies, IV bolus kisspeptin-10 raised serum LH within minutes of administration. Continuous infusion (1.5 µg/kg/h) sustained LH elevation and raised testosterone over the study period. These effects were documented in both healthy men and in men with type 2 diabetes and mild hypogonadism.^[5][6]

Kisspeptin does not directly supply testosterone, estradiol, or any gonadal hormone. Its effects are mediated by the body's own HPG axis. If GnRH neurons are active and the pituitary and gonads are functional, kisspeptin can drive the full cascade. If any downstream node is absent or dysfunctional, the cascade does not complete.

Does kisspeptin raise testosterone?

In published research in men, yes — via an indirect upstream mechanism. Kisspeptin-10 IV infusion (1.5 µg/kg/h) raised mean LH from 5.2 to 14.1 IU/L and elevated serum testosterone in healthy men (George 2011, JCEM).^[5]

In men with type 2 diabetes and mild biochemical hypogonadism, kisspeptin-10 at 0.3 µg/kg IV raised LH approximately 2-fold and brought testosterone into the normal physiological range over an 11-hour observation period, with no evidence of desensitization during the study (George 2013, Clinical Endocrinology).^[6]

Kisspeptin acts at the hypothalamus, upstream of the pituitary and gonads. It is not a direct testosterone replacement. Its testosterone-raising effect is contingent on intact GnRH, LH, and testicular function downstream. See the frequently asked questions for additional context on mechanism and dosing.